Study to Assess the Feasibility in Bile cfDNA of Resectable Biliary Tract Carcinomas
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT05783973 |
Recruitment Status :
Recruiting
First Posted : March 24, 2023
Last Update Posted : May 30, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
This Study Aims to Reveal the Effectiveness, Accuracy, and Feasibility in Bile | Diagnostic Test: Next generation sequencing |
In this study, we will investigate the potential of bile for genomic alterations using matched tissue, plasma and bile from 20 Resectable BTC Patients。The patient samples will be submitted for next-generation sequencing (NGS),The results will include but will not be limited to genomic profling, tumor mutation burden (TMB), microsatellite instability (MSI) status, homologous recombination repair deficiency (HRD)。Patients will be followed-up for treatment responses until radiological confirmation of disease recurrence ,The molecular assay results will then be analyzed with clinical data including objective responses disease-free survival outcomes, among others, to reveal the effectiveness, accuracy, and feasibility in bile, as compared to tissues and blood samples.
Baseline tissues, plasma and sputum samples from 20 Resectable BTC Patients with 520 Panel sequencing (tissue 1000X, ,plasma cfDNA 10000X,bile 10000X), in different methods will be compared.
Study Type : | Observational |
Estimated Enrollment : | 20 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | A Single-Center Exploratory Study to Assess the Feasibility in Bile cfDNA of Resectable Biliary Tract Carcinomas by Using Burning Rock Gene Testing Platform |
Actual Study Start Date : | February 2, 2023 |
Estimated Primary Completion Date : | December 31, 2023 |
Estimated Study Completion Date : | February 2, 2024 |
Group/Cohort | Intervention/treatment |
---|---|
bile group
bile samples from 20 resectable BTC patients with 520 Panel sequencing (bile10000X)
|
Diagnostic Test: Next generation sequencing
Extract DNA from bile,tissue and tissue sample, minimum DNA amount should be over 50ng. |
Tissue group
tissue samples from 20 resectable BTC patients with 520 Panel sequencing (tissue1000X)
|
Diagnostic Test: Next generation sequencing
Extract DNA from bile,tissue and tissue sample, minimum DNA amount should be over 50ng. |
Plasma group
plasma samples from 20 resectable BTC patients with 520 Panel sequencing (plasma 10000X)
|
Diagnostic Test: Next generation sequencing
Extract DNA from bile,tissue and tissue sample, minimum DNA amount should be over 50ng. |
- Compare different sample types with concordence rate, sensitivity, and specificity. [ Time Frame: 1 years ]
Concordance rate was defined as the fraction of the total number of true positive and true negative patients relative to the cohort or indicated subgroup; Sensitivity rate means true positive rate, true positive patients were defined as those who carried at least one genomic alteration that were detected in both matched samples.
Specificity rate means ture negative rate, patients were as defined true negative if no alteration was detected from either matched sample.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
Inclusion Criteria:
- Patients who are diagnosed with diagnosed with BTC (including IHCC、EHCC、GBC)by histology or cytology
- Patients who signed informed consent form;
- Patients who agree and have the ability to follow the planned research visits, provide surgical tissue, blood, and bile samples, provide clinical information, and cooperate with other research steps.
Exclusion Criteria:
a.Patients who be deemed unsuitable for enrollment by the researchers.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05783973
Contact: Changzhen Shang, MD | 13711279678 | shangchangzhen@139.com | |
Contact: Songyao Liu, MD | 13754858677 | liusy229@mail.sysu.edu.cn |
China, Guangdong | |
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University | Recruiting |
Guangzhou, Guangdong, China, 510289 | |
Contact: Songyao Liu, MD 13754858677 liusy229@mail.sysu.edu.cn |
Principal Investigator: | Changzhen Shang, MD | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
Responsible Party: | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
ClinicalTrials.gov Identifier: | NCT05783973 |
Other Study ID Numbers: |
SYSKY-2023-043-02 |
First Posted: | March 24, 2023 Key Record Dates |
Last Update Posted: | May 30, 2023 |
Last Verified: | February 2023 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
resectable BTC,tissue, blood , and bile samples,genomic alterations |
Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms |